Q&A: Targeting APRIL in IgA Nephropathy Shows Promise
Edgar Lerma, MD, provides insights into the pathophysiology of IgA nephropathy (IgAN) and the therapeutic promise of targeting APRIL.
Read More
Author: Teresa Sellinger
Shannon, Part 2: A Screwy Situation
This medical fiction takes place in a chaotic ED where a nurse is assigned an impossible case. As the patient defies all odds, a shocking crime unfolds.
Read More
7 Risk Factors Identified for Cognitive Impairment in COPD
Given the rising prevalence of cognitive impairment in COPD, researchers have called for increased efforts to identify risk factors and intervene earlier.
Read More
Aligning Clinical & Patient Perspectives to Strengthen PsA Management
A new study explores gaps in how patients and physicians view psoriatic arthritis (PsA) and recommends ways for clinicians to improve PsA management.
Read More
Comorbidity Burden Tied to Risk for Adverse Events in MS
A higher comorbidity burden was associated with an increased rate of AESI and early discontinuation among patients with MS in clinical trials of DMTs.
Read More
Pre-Relapse Immune Signature Implicates EBV Reactivation in MS Relapse
Researchers identified a monocyte/dendritic cell response to EBV reactivation in B cells as one of the earliest events in developing MS relapse.
Read More
Immunomodulatory Potential of Ketogenic Diet in MS Confirmed
Research found that following a ketogenic diet for 6 months can reprogram immune cell metabolism and promote anti-inflammatory phenotypes in patients with MS.
Read More
Paramagnetic Rim Lesions Predict Effectiveness of Tolebrutinib
Results of a post hoc analysis of 3 phase 3 trials of tolebrutinib suggest that PRLs are associated with an increased risk for disability accumulation in MS.
Read More
MS Activity Remains Low on Long-Term Fenebrutinib
Participants receiving the potent and highly selective BTK inhibitor fenebrutinib maintained low disease activity in the OLE of the FENopta study.
Read More
Ofatumumab: Good Initial Adherence & Treatment Satisfaction
Participants in the novel EAFToS study had high adherence rates to initiation and maintenance doses of ofatumumab in the first interim analysis.
Read More
Update on Safety Profile of Cladribine Tablets Yields Positive Results
The post-approval safety profile of cladribine tablets in relapsing MS was updated, with results consistent with development program findings and prior updates.
Read More
Higher-Dosed Ocrelizumab Associated With Less Disability Accrual
Researchers found that higher ocrelizumab exposure over 10 years was associated with less risk of disability progression in patients with multiple sclerosis.
Read More
Atypical & Radiological-Only Presentations Often Meet 2024 MS Criteria
Using the 2024 McDonald Criteria revisions around 30% of patients with atypical clinical symptoms or radiological-only presentation meet MS diagnostic criteria.
Read More
Key Results From the 2025 NRMP Match
The National Resident Matching Program (NRMP) shared results from the 2025 Main Residency Match, the largest in its history.
Read More
Strategies for Communicating Cancer Diagnoses Effectively in Hematology
Mohamad Mohty, MD, PhD, spoke with Physician’s Weekly about strategies that can help make it easier for clinicians communicating cancer diagnoses.
Read More
Q&A: A Pediatrics Perspective on the NRMP Match Process
Corinne L. Bria, MD, MEd, and Samuel Mikhail, MD, share insights on the NRMP Match process from a pediatrics program perspective.
Read More
Addressing Acute Pain & Related Challenges: Will Recent FDA Approval of a Novel Non-Opioid Analgesic Be a Game Changer?
FDA approval of a novel non-opioid analgesic will hopefully address the needs of many patients with acute pain and improve clinical outcomes and QOL.
Read More
Using Targeted Interventions to Elevate QOL & Symptom Control in Plaque Psoriasis
Recent study findings highlight the value of integrating behavioral modification and Health Belief Model–based education into plaque psoriasis management.
Read More